P53 as a target in myeloproliferative neoplasms

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1052-1053

  Lu, Min ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; JANUS KINASE 2 INHIBITOR; LA ANTIGEN; NUTLIN 3; PEGINTERFERON ALPHA2A; PROTEIN MDM2; PROTEIN P53; RG 7112; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL CYCLE ARREST; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; SENESCENCE; THROMBOCYTHEMIA; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84872808860     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.719     Document Type: Editorial

References (10)

1. James C, Ugo V, Le Couédic JP, et at. Nature. 2005;434(7037):1144-8.
2. Nakatake M, Monte-Mor B, Debili N, et al. Oncogene. 2012;31(10):1323-33
3. Lu M, Wang X, Li Y, et al. Blood. 2012; 120():3098-3105
4. Vassilev LT. Trends Mol Med. 2007;13(1):23-31.
5. Vassilev LT, Vu BT, Graves B, et al. Science. 2004; 303(5659):844-8.
6. Verstovsek S, Mesa RA, Gotlib J, et al. N Engl J Med. 2012;366(9):799-807.
7. Kiladjian JJ, Mesa RA, Hoffman R. Blood. 2011;117(18):4706-15.
8. Lu M, Zhang W, Berenzon D, et al. Exp Hematol. 2010;38(6):472-80.
9. Townsend PA, Scarabelli TM, Davidson SM, et al. J Biol Chem. 2004;279(7):5811-20.
10. Andreeff M, Kojima K, Padmanabhan S, et al. Blood. 2010; 116: 657